Aquestive Therapeutics (NASDAQ:AQST) CEO Sells $753,423.09 in Stock

Aquestive Therapeutics, Inc. (NASDAQ:AQST) CEO Daniel Barber sold 180,677 shares of the company’s stock in a transaction that occurred on Tuesday, March 10th. The shares were sold at an average price of $4.17, for a total value of $753,423.09. Following the completion of the transaction, the chief executive officer directly owned 1,004,753 shares of the company’s stock, valued at $4,189,820.01. This represents a 15.24% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Aquestive Therapeutics Trading Up 2.5%

NASDAQ:AQST traded up $0.11 during mid-day trading on Wednesday, hitting $4.31. 1,170,828 shares of the company’s stock were exchanged, compared to its average volume of 5,614,740. Aquestive Therapeutics, Inc. has a fifty-two week low of $2.12 and a fifty-two week high of $7.55. The firm has a market capitalization of $525.38 million, a P/E ratio of -5.52 and a beta of 1.61. The company has a 50 day simple moving average of $4.13 and a 200-day simple moving average of $5.22.

Aquestive Therapeutics (NASDAQ:AQST) last announced its quarterly earnings results on Wednesday, March 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.13). The business had revenue of $13.02 million for the quarter, compared to analysts’ expectations of $13.28 million. As a group, analysts expect that Aquestive Therapeutics, Inc. will post -0.46 earnings per share for the current year.

Institutional Investors Weigh In On Aquestive Therapeutics

Large investors have recently modified their holdings of the company. NewEdge Advisors LLC acquired a new position in Aquestive Therapeutics in the third quarter valued at $28,000. BNP Paribas Financial Markets raised its position in shares of Aquestive Therapeutics by 78.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 9,413 shares of the company’s stock worth $31,000 after acquiring an additional 4,134 shares in the last quarter. Modern Wealth Management LLC bought a new position in shares of Aquestive Therapeutics in the 2nd quarter worth about $33,000. Cox Capital Mgt LLC acquired a new position in shares of Aquestive Therapeutics in the 3rd quarter valued at about $59,000. Finally, Kestra Private Wealth Services LLC acquired a new position in shares of Aquestive Therapeutics in the 3rd quarter valued at about $60,000. 32.45% of the stock is currently owned by institutional investors and hedge funds.

More Aquestive Therapeutics News

Here are the key news stories impacting Aquestive Therapeutics this week:

• Positive Sentiment: Analyst note/valuation — A Seeking Alpha write‑up reiterates a Buy on AQST and argues Anaphylm is closer to FDA approval after addressing CRL packaging/labeling issues; the author models an $8 fair value (≈87% upside), high adoption probabilities and eventual profitability by 2029 while warning additional financing may be needed by end‑2027. Aquestive Therapeutics: With Some Hiccups, Anaphylm Is Closer To FDA Approval
• Positive Sentiment: Broker upgrades/estimate revisions — HC Wainwright raised several near‑term EPS estimates (Q1–Q4 2026 and select 2027 quarters) and lifted its FY2026 view (from roughly -$0.61 to -$0.51), signaling modestly improved operating outlook assumptions. This reduces downside to short‑term guidance risk but the company remains loss‑making. AQST Stock Page
• Neutral Sentiment: Industry coverage — The Globe and Mail included Aquestive in a list of healthcare stocks analysts are bullish on, providing supportive media attention but no company‑specific catalytic news. Analysts Are Bullish on These Healthcare Stocks: Teva Pharmaceutical (TEVA), Aquestive Therapeutics (AQST)
• Neutral Sentiment: Corporate governance — Aquestive granted an inducement equity award to its Chief Medical Officer under Nasdaq rules; standard retention/compensation action (minor dilution/expense implications). Aquestive Therapeutics Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4)
• Negative Sentiment: Legal risk — Multiple law firms (Rosen, Johnson Fistel, Bernstein Liebhard, Faruqi & Faruqi, Gross Law) have announced or are soliciting plaintiffs for securities class actions covering purchases from June 16, 2025 to Jan 8, 2026; litigation could increase legal costs, management distraction and limit upside until resolved. Note deadlines for lead plaintiff motions are being publicized (e.g., May 4, 2026). AQST Investors Encouraged to Seek Lead Plaintiff Role in Aquestive Therapeutics Securities Class Action Case with Johnson Fistel
• Negative Sentiment: Market data anomaly — Short‑interest reports show a reported surge but contain inconsistent/erroneous values (zeros/NaN). If real, rising short interest would add selling pressure; current published figures appear unreliable and should be confirmed via exchange filings. (No external link provided.)

Analyst Ratings Changes

Several research analysts recently issued reports on AQST shares. Lake Street Capital set a $6.00 target price on Aquestive Therapeutics in a research report on Tuesday, February 3rd. Wall Street Zen raised Aquestive Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Aquestive Therapeutics in a research report on Wednesday, January 21st. Two investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $8.80.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.